LETROZOLE DEXCEL

País: Israel

Língua: inglês

Origem: Ministry of Health

Ingredientes ativos:

LETROZOLE

Disponível em:

DEXCEL LTD, ISRAEL

Código ATC:

L02BG04

Forma farmacêutica:

FILM COATED TABLETS

Composição:

LETROZOLE 2.5 MG

Via de administração:

PER OS

Tipo de prescrição:

Required

Fabricado por:

HAUPT PHARMA MUNSTER GmbH, GERMANY

Grupo terapêutico:

LETROZOLE

Área terapêutica:

LETROZOLE

Indicações terapêuticas:

Letrozole - Dexcel tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole - Dexcel is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Data de autorização:

2016-02-29